Great Point Partners LLC 13F holdings
Great Point Partners LLC reported 37 positions with a total reported value of $424.4M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: VOR VOR BIOPHARMA INC (7.4%), ABVX ABIVAX SA (6.4%), VERA VERA THERAPEUTICS INC (6.1%), ZURA ZURA BIO LTD (5.9%), ALMS ALUMIS INC (5.7%). Against 2026-03-31 it opened 10 new positions and exited 12. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Great Point Partners LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 37 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| VOR VOR BIOPHARMA INC | 1,700,000 | $31.3M | 7.4% |
| ABVX ABIVAX SA | 204,314 | $27.2M | 6.4% |
| VERA VERA THERAPEUTICS INC | 600,836 | $25.8M | 6.1% |
| ZURA ZURA BIO LTD | 4,215,930 | $24.9M | 5.9% |
| ALMS ALUMIS INC | 856,061 | $24.1M | 5.7% |
| SLGL SOL-GEL TECHNOLOGIES LTD | 274,363 | $20.3M | 4.8% |
| DFTX DEFINIUM THERAPEUTICS INC | 425,000 | $20.0M | 4.7% |
| ANNX ANNEXON INC | 3,500,000 | $20.0M | 4.7% |
| ORKA ORUKA THERAPEUTICS INC | 183,330 | $17.4M | 4.1% |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | 855,813 | $16.7M | 3.9% |
| SGMT SAGIMET BIOSCIENCES INC | 2,029,933 | $15.7M | 3.7% |
| CTNM CONTINEUM THERAPEUTICS INC | 921,481 | $15.1M | 3.6% |
| IMMX IMMIX BIOPHARMA INC | 1,277,642 | $13.2M | 3.1% |
| CLYM CLIMB BIO INC | 1,000,000 | $13.0M | 3.1% |
| AMLX AMYLYX PHARMACEUTICALS INC | 700,000 | $12.6M | 3.0% |
| NKTR NEKTAR THERAPEUTICS | 175,000 | $12.2M | 2.9% |
| NGNE NEUROGENE INC | 352,180 | $11.1M | 2.6% |
| LBRX LB PHARMACEUTICALS INC | 317,221 | $10.3M | 2.4% |
| IRD OPUS GENETICS INC | 1,970,187 | $8.1M | 1.9% |
| EPRX EUPRAXIA PHARMACEUTICALS INC | 1,200,000 | $7.9M | 1.9% |
| DRUG BRIGHT MINDS BIOSCIENCES INC | 109,603 | $7.7M | 1.8% |
| IFRX INFLARX NV | 3,046,557 | $6.8M | 1.6% |
| RLMD RELMADA THERAPEUTICS INC | 842,106 | $5.8M | 1.4% |
| JATT JATT II ACQUISITION CORP | 500,000 | $5.7M | 1.3% |
| CGEM CULLINAN THERAPEUTICS INC | 300,000 | $5.5M | 1.3% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 10 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ABVX ABIVAX SA | 204,314 | $27.2M | 6.4% |
| DFTX DEFINIUM THERAPEUTICS INC | 425,000 | $20.0M | 4.7% |
| SGMT SAGIMET BIOSCIENCES INC | 2,029,933 | $15.7M | 3.7% |
| IFRX INFLARX NV | 3,046,557 | $6.8M | 1.6% |
| JATT JATT II ACQUISITION CORP | 500,000 | $5.7M | 1.3% |
| ALT ALTIMMUNE INC | 1,741,232 | $5.3M | 1.2% |
| AMAN AMANAT ACQUISITION CORP | 500,000 | $5.1M | 1.2% |
| ELVN ENLIVEN THERAPEUTICS INC | 70,000 | $3.6M | 0.8% |
| RNTX REIN THERAPEUTICS INC | 2,575,000 | $2.7M | 0.6% |
| DBVT DBV TECHNOLOGIES S A | 156,906 | $2.6M | 0.6% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 12 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| APGE APOGEE THERAPEUTICS INC | 374,000 | $31.5M | 7.7% |
| KALVISTA PHARMACEUTICALS INC | 675,000 | $13.6M | 3.3% |
| IMVT IMMUNOVANT INC | 545,625 | $13.6M | 3.3% |
| JBIO JADE BIOSCIENCES INC | 964,462 | $13.6M | 3.3% |
| ZBIO ZENAS BIOPHARMA INC | 524,066 | $10.2M | 2.5% |
| CMPX COMPASS THERAPEUTICS INC | 1,350,000 | $7.1M | 1.7% |
| CNTX CONTEXT THERAPEUTICS INC | 2,238,496 | $5.9M | 1.4% |
| UNCY UNICYCIVE THERAPEUTICS INC | 796,558 | $5.2M | 1.3% |
| TENX TENAX THERAPEUTICS INC | 327,307 | $5.2M | 1.3% |
| PHVS PHARVARIS N V | 82,800 | $2.3M | 0.6% |
| AVTX AVALO THERAPEUTICS INC | 124,666 | $1.9M | 0.5% |
| ALKS ALKERMES PLC | 50,000 | $1.8M | 0.4% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| VERA VERA THERAPEUTICS INC | 199,348 | 600,836 | +201.4% | $25.8M |
| IMMX IMMIX BIOPHARMA INC | 350,000 | 1,277,642 | +265.0% | $13.2M |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | 500,000 | 855,813 | +71.2% | $16.7M |
| IRD OPUS GENETICS INC | 324,340 | 1,970,187 | +507.4% | $8.1M |
| ANNX ANNEXON INC | 2,500,000 | 3,500,000 | +40.0% | $20.0M |
| CTNM CONTINEUM THERAPEUTICS INC | 800,198 | 921,481 | +15.2% | $15.1M |
| LBRX LB PHARMACEUTICALS INC | 300,000 | 317,221 | +5.7% | $10.3M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| SCYX SCYNEXIS INC | 7,554,347 | 944,292 | -87.5% | $3.8M |
| AMLX AMYLYX PHARMACEUTICALS INC | 1,750,000 | 700,000 | -60.0% | $12.6M |
| NKTR NEKTAR THERAPEUTICS | 316,453 | 175,000 | -44.7% | $12.2M |
| DRUG BRIGHT MINDS BIOSCIENCES INC | 220,000 | 109,603 | -50.2% | $7.7M |
| SLN SILENCE THERAPEUTICS PLC | 1,020,489 | 450,000 | -55.9% | $4.9M |
| NGNE NEUROGENE INC | 500,000 | 352,180 | -29.6% | $11.1M |
| CLYM CLIMB BIO INC | 1,334,130 | 1,000,000 | -25.0% | $13.0M |
| PMN PROMIS NEUROSCIENCES INC | 371,402 | 86,150 | -76.8% | $1.1M |
| PALI PALISADE BIO INC | 3,405,757 | 2,284,819 | -32.9% | $4.8M |
| VOR VOR BIOPHARMA INC | 1,750,000 | 1,700,000 | -2.9% | $31.3M |
CIK 1281446 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
